Age at Kasai, spleen issues key to biliary atresia outcomes
Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more likely to have poor outcomes…
News
Canada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…
Blood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
Targeting mitochondrial problems eases cholestasis in mouse model
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…
Drug for fatty liver disease MASH may help prevent transplants
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
FDA gives conditional approval to Wegovy for some liver patients
The U.S. Food and Drug Administration (FDA) has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat certain people with metabolic dysfunction-associated steatohepatitis (MASH), a…
Treatment of hepatitis B needs global overhaul, per WHO study
Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also to retain them for long-term…
Chemomab, FDA align on key aspects of nebokitug development
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
Maternal liver damage markers can predict twin pregnancy outcomes
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by intrahepatic cholestasis of pregnancy…
NorUDCA becomes first MASLD therapy approved in India
India’s Central Drugs Standard Control Organization has approved the oral therapy nor-ursodeoxycholic acid (NorUDCA) for people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…